There's two newly dropped blends of glow, glow and glow
61.9%, respectively) 34 and a post-hoc analysis of this trial showed a 6069% mean 10-years relative risk reduction of T2D development 75
Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Fras JP, et al
Again, you just wrote a book to try to help primary care physicians think through this, but how prepared are primary care physicians now to have this kind of conversation in which we consider seriously lifestyle and what that can accomplish, but also we don't just either rush to the GLP-1 or say no, you don't need that
doi: 10.1016/0006-2952(74)90198-1